Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors

Background Endoscopic ultrasound‐guided fine‐needle aspiration is associated with the accurate determination of tumor grade. However, because it is an invasive procedure there is a need to explore alternative noninvasive procedures. Purpose To develop and validate a noncontrast radiomics model for t...

Full description

Saved in:
Bibliographic Details
Published inJournal of magnetic resonance imaging Vol. 52; no. 4; pp. 1124 - 1136
Main Authors Bian, Yun, Zhao, Zengrui, Jiang, Hui, Fang, Xu, Li, Jing, Cao, Kai, Ma, Chao, Guo, Shiwei, Wang, Li, Jin, Gang, Lu, Jianping, Xu, Jun
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.10.2020
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Endoscopic ultrasound‐guided fine‐needle aspiration is associated with the accurate determination of tumor grade. However, because it is an invasive procedure there is a need to explore alternative noninvasive procedures. Purpose To develop and validate a noncontrast radiomics model for the preoperative prediction of nonfunctional pancreatic neuroendocrine tumor (NF‐pNET) grade (G). Study Type Retrospective, single‐center study. Subjects Patients with pathologically confirmed PNETs (139) were included. Field Strength/Sequence 3T/breath‐hold single‐shot fast‐spin echo T2‐weighted sequence and unenhanced and dynamic contrast‐enhanced T1‐weighted fat‐suppressed sequences. Assessment Tumor features on contrast MR images were evaluated by three board‐certified abdominal radiologists. Statistical Tests Multivariable logistic regression analysis was used to develop the clinical model. The least absolute shrinkage and selection operator method and linear discriminative analysis (LDA) were used to select the features and to construct a radiomics model. The performance of the models was assessed using the training cohort (97 patients) and the validation cohort (42 patients), and decision curve analysis (DCA) was applied for clinical use. Results The clinical model included 14 imaging features, and the corresponding area under the curve (AUC) was 0.769 (95% confidence interval [CI], 0.675–0.863) in the training cohort and 0.729 (95% CI, 0.568–0.890) in the validation cohort. The LDA included 14 selected radiomics features that showed good discrimination—in the training cohort (AUC, 0.851; 95% CI, 0.758–0.916) and the validation cohort (AUC, 0.736; 95% CI, 0.518–0.874). In the decision curves, if the threshold probability was 0.17–0.84, using the radiomics score to distinguish NF‐pNET G1 and G2/3, offered more benefit than did the use of a treat‐all‐patients or treat‐none scheme. Data Conclusion The developed radiomics model using noncontrast MRI could help differentiate G1 and G2/3 tumors, to make the clinical decision, and screen pNETs grade. Level of Evidence 4 Technical Efficacy Stage 2 J. Magn. Reson. Imaging 2020;52:1124–1136.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Yun Bian and Zengrui Zhao are the joint first authors in the paper.
ISSN:1053-1807
1522-2586
1522-2586
DOI:10.1002/jmri.27176